Virax Biolabs Group (VRAX) Competitors $1.87 +0.05 (+2.75%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$2.07 +0.20 (+10.70%) As of 02/21/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends VRAX vs. LIAN, NXTC, LPTX, INAB, APRE, OKUR, SNTI, MIRA, MRKR, and LPCNShould you be buying Virax Biolabs Group stock or one of its competitors? The main competitors of Virax Biolabs Group include LianBio (LIAN), NextCure (NXTC), Leap Therapeutics (LPTX), IN8bio (INAB), Aprea Therapeutics (APRE), OnKure Therapeutics (OKUR), Senti Biosciences (SNTI), MIRA Pharmaceuticals (MIRA), Marker Therapeutics (MRKR), and Lipocine (LPCN). These companies are all part of the "pharmaceutical products" industry. Virax Biolabs Group vs. LianBio NextCure Leap Therapeutics IN8bio Aprea Therapeutics OnKure Therapeutics Senti Biosciences MIRA Pharmaceuticals Marker Therapeutics Lipocine Virax Biolabs Group (NASDAQ:VRAX) and LianBio (NASDAQ:LIAN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, community ranking, dividends, earnings, analyst recommendations, valuation and risk. Do institutionals and insiders hold more shares of VRAX or LIAN? 8.6% of Virax Biolabs Group shares are held by institutional investors. Comparatively, 74.8% of LianBio shares are held by institutional investors. 45.1% of Virax Biolabs Group shares are held by insiders. Comparatively, 7.6% of LianBio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has better valuation & earnings, VRAX or LIAN? Virax Biolabs Group has higher revenue and earnings than LianBio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVirax Biolabs Group$84.87K71.23-$6.73MN/AN/ALianBioN/AN/A-$110.29M-$0.81-0.25 Does the media favor VRAX or LIAN? In the previous week, LianBio had 1 more articles in the media than Virax Biolabs Group. MarketBeat recorded 1 mentions for LianBio and 0 mentions for Virax Biolabs Group. LianBio's average media sentiment score of 0.75 beat Virax Biolabs Group's score of 0.00 indicating that LianBio is being referred to more favorably in the news media. Company Overall Sentiment Virax Biolabs Group Neutral LianBio Positive Does the MarketBeat Community believe in VRAX or LIAN? LianBio received 4 more outperform votes than Virax Biolabs Group when rated by MarketBeat users. CompanyUnderperformOutperformVirax Biolabs GroupN/AN/ALianBioOutperform Votes436.36% Underperform Votes763.64% Which has more volatility and risk, VRAX or LIAN? Virax Biolabs Group has a beta of 1.63, indicating that its stock price is 63% more volatile than the S&P 500. Comparatively, LianBio has a beta of 0.23, indicating that its stock price is 77% less volatile than the S&P 500. Is VRAX or LIAN more profitable? Virax Biolabs Group's return on equity of 0.00% beat LianBio's return on equity.Company Net Margins Return on Equity Return on Assets Virax Biolabs GroupN/A N/A N/A LianBio N/A -33.17%-30.19% SummaryVirax Biolabs Group beats LianBio on 6 of the 10 factors compared between the two stocks. Get Virax Biolabs Group News Delivered to You Automatically Sign up to receive the latest news and ratings for VRAX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VRAX vs. The Competition Export to ExcelMetricVirax Biolabs GroupDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.05M$2.30B$5.84B$9.14BDividend YieldN/A0.75%4.75%3.85%P/E RatioN/A5.0426.0419.11Price / Sales71.2362.84447.4676.36Price / CashN/A15.7538.0134.83Price / Book0.943.287.644.62Net Income-$6.73M-$65.73M$3.18B$245.85M7 Day Performance-1.80%-4.01%-2.00%-2.61%1 Month Performance-12.62%-9.02%-0.44%-2.14%1 Year Performance110.11%-15.61%16.44%12.98% Virax Biolabs Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VRAXVirax Biolabs Group0.8384 of 5 stars$1.87+2.7%N/A+93.9%$6.05M$84,872.000.005LIANLianBioN/A$0.19flatN/A-95.7%$20.88MN/A-0.24110News CoverageGap DownNXTCNextCure4.0526 of 5 stars$0.74-2.8%$4.00+441.6%-55.9%$20.69MN/A-0.3590LPTXLeap Therapeutics1.3579 of 5 stars$0.54+5.6%$4.92+814.7%-84.0%$20.60MN/A-0.2840INABIN8bio3.7383 of 5 stars$0.27+3.9%$7.75+2,769.3%-73.6%$19.58MN/A-0.3620Gap DownAPREAprea Therapeutics2.1253 of 5 stars$3.59-6.3%$15.50+331.8%-58.3%$19.49M$580,000.00-1.287Gap UpOKUROnKure Therapeutics2.6327 of 5 stars$5.82-0.5%$36.00+518.6%N/A$19.44MN/A-0.48N/AGap UpSNTISenti Biosciences2.3791 of 5 stars$4.02-3.1%$10.00+148.8%-5.3%$19.38M$2.56M-0.264MIRAMIRA Pharmaceuticals2.1128 of 5 stars$1.17+1.7%$14.00+1,096.6%+1.9%$19.38MN/A-2.092MRKRMarker Therapeutics4.3474 of 5 stars$1.72-2.8%$19.00+1,004.7%-59.9%$18.96M$3.31M0.0060LPCNLipocine1.6881 of 5 stars$3.50flat$10.00+185.7%-14.4%$18.73M$500,000.00-4.6110Analyst ForecastGap Down Related Companies and Tools Related Companies LianBio Competitors NextCure Competitors Leap Therapeutics Competitors IN8bio Competitors Aprea Therapeutics Competitors OnKure Therapeutics Competitors Senti Biosciences Competitors MIRA Pharmaceuticals Competitors Marker Therapeutics Competitors Lipocine Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VRAX) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredA strange twist 500 miles from WashingtonEnergy is life. And this year, it could also make national heroes out of President Trump and VP Vance. ...Porter & Company | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virax Biolabs Group Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Virax Biolabs Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
